Soluble CD14 is a nonspecific marker of monocyte activation

AIDS

Volumn 29, Issue 10, 2015, Pages 1263-1265

  Shive, Carey L ^a   Jiang, Wei ^b   Anthony, Donald D ^a,c   Lederman, Michael M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SOLUBLE CD4 ANTIGEN; TOLL LIKE RECEPTOR; BIOLOGICAL MARKER; CD14 ANTIGEN; CYTOKINE;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; HIV ELISA KIT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE ACTIVATION; MONOCYTE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; BLOOD; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM;

ANTIGENS, CD14; BIOMARKERS; CELLS, CULTURED; CYTOKINES; HUMANS; MONOCYTES;

EID: 84942906755     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000735     Document Type: Article

References (23)

1. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
2. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-1259.
3. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. J Infect Dis 2014; 210:1228-1238.
4. Lien E, Aukrust P, Sundan A, Muller F, Froland SS, Espevik T. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 1998; 92:2084-2092.
5. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204:1217-1226.
6. Mendez-Lagares G, Romero-Sanchez MC, Ruiz-Mateos E, Genebat M, Ferrando-Martínez S, Muñoz-Fernández MA, et al. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis 2013; 207:1221-1225.
7. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-1567.
8. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-1430.
9. Marcos V, Latzin P, Hector A, Sonanini S, Hoffmann F, Lacher M, et al. Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases. Respir Res 2010; 11:32-44.
10. SandlerNG, Koh C, Roque A, Eccleston JL, Siegel RB, DeMino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-123030 e1-3.
11. Schlatzer DM, Sugalski JM, Chen Y, Barnholtz-Sloan J, Davitkov P, Hazlett FZ, et al. Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections. J Acquir Immune Defic Syndr 2013; 63:563-571.
12. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J Immunol 2004; 172:4470-4479.
13. Bazil V, Strominger JL. Shedding as a mechanism of downmodulation of CD14 on stimulated human monocytes. J Immunol 1991; 147:1567-1574.
14. Bufler P, Stiegler G, Schuchmann M, Hess S, Kruger C, Stelter F, et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur J Immunol 1995; 25:604-610.
15. Durieux JJ, Vita N, Popescu O, Guette G, Calzada-Wack J, Munker R, et al. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol 1994; 24:2006-2012.
16. Stelter F, Pfister M, Bernheiden M, Jack R, Bufler P, Engelmann H, et al. The myeloid differentiation antigen CD14 is N-And O-glycosylated. Contribution of N-linked glycosylation to different soluble CD14 isoforms. Eur J Biochem 1996; 236:457-464.
17. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11:225-229.
18. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433.
19. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
20. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000; 164:13-17.
21. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, et al. CD14 is a pattern recognition receptor. Immunity 1994; 1:509-516.
22. Wang PY, Kitchens RL, Munford RS. Phosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide. J Biol Chem 1998; 273:24309-24313.
23. Yu B, Hailman E, Wright SD. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 1997; 99:315-324.